IP Library › Granted Patent US 12,558,309
Granted Patent B2
US 12,558,309 · App. 18/468,542 · Granted Feb 24, 2026

Method for morselizing and/or targeting pharmaceutically active principles to synovial tissue

Inventors: Georges Gaudriault (Montpellier, FR); Sylvestre Grizot (Le Crès, FR); Mark Hurtig (Ontario, CA); Matthew Shive (Denver, CO)
Assignee: MEDINCELL S.A.
A61K9/0024A61K31/192A61K31/415A61K45/06A61K47/34A61P19/02
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,558,309
App. No.
18/468,542
Granted
Feb 24, 2026
Kind
B2
Abstract

A method of targeting to the synovial tissue biodegradable drug delivery compositions or morselizing biodegradable drug delivery compositions are described. The biodegradable drug composition comprises a triblock copolymer containing a polyester and a polyethylene glycol and a diblock copolymer containing a polyester and an end-capped polyethylene glycol, as well as at least one pharmaceutically active principle is disclosed.

Claims (23)

1 . A biodegradable drug delivery composition comprising:

i) only a single biodegradable triblock copolymer and only a single biodegradable diblock copolymer, wherein

(a) the single biodegradable triblock copolymer has the formula:

PLA v -PEG w -PLA x

wherein v and x are the number of repeat units ranging from 24 to 682 and w is the number of repeat units ranging from 4 to 273 and v=x or v≠x; and

(b) the single biodegradable diblock copolymer has the formula:

mPEG y -PLA z

wherein y is the number of repeat units with y ranging from 3 to 45 and z ranging from 7 to 327, wherein the ratio of the biodegradable triblock copolymer of (a) and the biodegradable diblock copolymer of (b) is 3:2 to 1:19 in said biodegradable drug composition; and

ii) at least one pharmaceutically active principle which is delivered through morselization of said biodegradable drug delivery composition,

wherein said pharmaceutically active principle comprises a non-steroidal anti-inflammatory agent, and

the PEG chain in at least one of the triblock and diblock copolymers is about 2 kDa.

2 . The biodegradable drug delivery composition according to claim 1 , wherein said non-steroidal anti-inflammatory agent is etofenamate, celecoxib, apricoxib, rofecoxib, nabumetone, benorilate, etoricoxib, ampiroxicam, aminophemazone, valdecoxib, acetominophen, bufexamac, nimesulide, parecoxib, mefenamic acid, dexibuprofen, ibuprofen, flurbiprofen, aspirin, dexketoprofen, diclofenac, diflunisal, etodolac, fenoprofen, firocoxib, indomethacin, ketoprofen, ketorolac, lornoxicam, loxoprofen, loxomac, lumiracoxib, meclofenamic acid, meloxicam, naproxen, naprosyn, nimalox, oxaporozin, piroxicam, salsalate, sulindac, tenoxicam, tolfenamic acid, ropivicaine and mixtures thereof.

3 . A biodegradable drug delivery composition comprising:

i) only a single biodegradable triblock copolymer and only a single biodegradable diblock copolymer, wherein

(a) the single biodegradable triblock copolymer has the formula:

PLA v -PEG w -PLA x

wherein v and x are the number of repeat units ranging from 24 to 682 and w is the number of repeat units ranging from 4 to 273 and v=x or v≠x; and

(b) the single biodegradable diblock copolymer has the formula:

mPEG y -PLA z

wherein y is the number of repeat units with y ranging from 3 to 45 and z ranging from 7 to 327, wherein the ratio of the biodegradable triblock copolymer of (a) and the biodegradable diblock copolymer of (b) is 3:2 to 1:19 in said biodegradable drug composition; and

ii) at least one pharmaceutically active principle which is delivered through morselization of said biodegradable drug delivery composition,

wherein said pharmaceutically active principle comprises celecoxib, and

the PEG chain in at least one of the triblock and diblock copolymers is about 2 kDa.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 20, 2023
From: GAUDRIAULT, GEORGES; GRIZOT, SYLVESTRE; HURTIG, MARK; SHIVE, MATTHEW
To: MEDINCELL
Reel/Frame 064966/0043 →
CHANGE OF NAME Recorded Sep 20, 2023
From: MEDINCELL
To: MEDINCELL S.A.
Reel/Frame 064966/0053 →
Continuity (4)
Division 17156781 · Jan 25, 2021
Continuation 15776355
Provisional Application 62255778 · Nov 16, 2015
Related Publication 20240000703A1 · Jan 4, 2024
References Cited (181)
US 3043832A · Ruggieri et al. · 1962 [cited by applicant]
US 3377364A · Spero · 1968 [cited by applicant]
US 4526938A · Churchill et al. · 1985 [cited by applicant]
US 4745160A · Churchill et al. · 1988 [cited by applicant]
US 4938763A · Dunn et al. · 1990 [cited by applicant]
US 5077049A · Dunn et al. · 1991 [cited by applicant]
US 5221534A · DesLauriers et al. · 1993 [cited by applicant]
US 5278201A · Dunn et al. · 1994 [cited by applicant]
US 5278202A · Dunn et al. · 1994 [cited by applicant]
US 5340849A · Dunn et al. · 1994 [cited by applicant]
US 5518730A · Fuisz · 1996 [cited by applicant]
US 5548035A · Kim et al. · 1996 [cited by applicant]
US 5632727A · Tipton et al. · 1997 [cited by applicant]
US 5733950A · Dunn et al. · 1998 [cited by applicant]
US 5739176A · Dunn et al. · 1998 [cited by applicant]
US 5744153A · Yewey et al. · 1998 [cited by applicant]
US 5780044A · Yewey et al. · 1998 [cited by applicant]
US 5990194A · Dunn et al. · 1999 [cited by applicant]
US 6143314A · Chandrashekar et al. · 2000 [cited by applicant]
US 6194006B1 · Lyons et al. · 2001 [cited by applicant]
US 6206920B1 · Eliaz et al. · 2001 [cited by applicant]
US 6261583B1 · Dunn et al. · 2001 [cited by applicant]
US 6294204B1 · Rossling et al. · 2001 [cited by applicant]
US 6350812B1 · Vert et al. · 2002 [cited by applicant]
US 6379703B1 · Lyons et al. · 2002 [cited by applicant]
US RE37950E · Dunn et al. · 2002 [cited by applicant]
US 6565874B1 · Dunn et al. · 2003 [cited by applicant]
US 6592899B2 · Fowers et al. · 2003 [cited by applicant]
US 6596316B2 · Lyons et al. · 2003 [cited by applicant]
US 6630155B1 · Chandrashekar et al. · 2003 [cited by applicant]
US 6667061B2 · Ramstack et al. · 2003 [cited by applicant]
US 6773714B2 · Dunn et al. · 2004 [cited by applicant]
US 6916788B2 · Seo et al. · 2005 [cited by applicant]
US 7019106B2 · Yamamoto et al. · 2006 [cited by applicant]
US 7153520B2 · Seo et al. · 2006 [cited by applicant]
US 7160651B2 · McHugh et al. · 2007 [cited by applicant]
US 7301001B2 · Hossainy et al. · 2007 [cited by applicant]
US 7371406B2 · Ramstack et al. · 2008 [cited by applicant]
US 7649023B2 · Shih et al. · 2010 [cited by applicant]
US 8221778B2 · Siegel et al. · 2012 [cited by applicant]
US 8557865B2 · Waddell · 2013 [cited by applicant]
US 8642666B2 · Shih et al. · 2014 [cited by applicant]
US 8741327B2 · Siegel et al. · 2014 [cited by applicant]
US 8802127B2 · Siegel et al. · 2014 [cited by applicant]
US 8852638B2 · Luk et al. · 2014 [cited by applicant]
US 9023897B2 · Gaudriault · 2015 [cited by applicant]
US 9044450B2 · Luk et al. · 2015 [cited by applicant]
US 9265836B2 · Shih et al. · 2016 [cited by applicant]
US 9393310B2 · Zale et al. · 2016 [cited by applicant]
US 9439905B2 · Siegel et al. · 2016 [cited by applicant]
US 9579386B2 · Zale et al. · 2017 [cited by applicant]
US 9717799B2 · Siegel et al. · 2017 [cited by applicant]
US 9895447B2 · Siegel et al. · 2018 [cited by applicant]
US 9925268B2 · Siegel et al. · 2018 [cited by applicant]
US 10111960B2 · Siegel et al. · 2018 [cited by applicant]
US 11801217B2 · Roberge et al. · 2023 [cited by applicant]
US 20020028249A1 · Rickey et al. · 2002 [cited by applicant]
US 20030068377A1 · Fowers et al. · 2003 [cited by applicant]
US 20030139353A1 · Jackson et al. · 2003 [cited by applicant]
US 20030228366A1 · Shih et al. · 2003 [cited by applicant]
US 20040001872A1 · Shih et al. · 2004 [cited by applicant]
US 20040037885A1 · Seo et al. · 2004 [cited by applicant]
US 20040185104A1 · Piao et al. · 2004 [cited by applicant]
US 20050112170A1 · Hossainy et al. · 2005 [cited by applicant]
US 20050186261A1 · Avelar et al. · 2005 [cited by applicant]
US 20060034889A1 · Jo et al. · 2006 [cited by applicant]
US 20070104759A1 · Dunn et al. · 2007 [cited by applicant]
US 20080247987A1 · Liggins et al. · 2008 [cited by applicant]
US 20080305140A1 · Siegel et al. · 2008 [cited by applicant]
US 20090004243A1 · Pacetti et al. · 2009 [cited by applicant]
US 20090198248A1 · Yeung · 2009 [cited by examiner]
US 20090264472A1 · Wohabrebbi et al. · 2009 [cited by applicant]
US 20120172454A1 · Gaudriault · 2012 [cited by examiner]
US 20160310601A1 · Thanoo et al. · 2016 [cited by applicant]
US 20170196855A1 · Ahmed et al. · 2017 [cited by applicant]
US 20190105396A1 · Siegel et al. · 2019 [cited by applicant]
US 20190160171A1 · Gaudriault et al. · 2019 [cited by applicant]
US 20190167839A1 · Shalaby et al. · 2019 [cited by applicant]
US 20190192665A1 · Gaudriault · 2019 [cited by applicant]
CA 2530003A1 · 2004 [cited by applicant]
CA 2822854A1 · 2012 [cited by applicant]
CA 2877083A1 · 2014 [cited by applicant]
CA 2938019A1 · 2015 [cited by applicant]
CN 1413118A · 2003 [cited by applicant]
CN 1516581A · 2004 [cited by applicant]
CN 1717224A · 2006 [cited by applicant]
CN 1897930A · 2007 [cited by applicant]
CN 101052684A · 2007 [cited by applicant]
CN 101810560A · 2010 [cited by applicant]
EP 0343850A2 · 1989 [cited by applicant]
EP 0436667B1 · 1997 [cited by applicant]
EP 1125577A2 · 2001 [cited by applicant]
EP 0773034B1 · 2002 [cited by applicant]
EP 1126822B1 · 2004 [cited by applicant]
EP 1322286B1 · 2005 [cited by applicant]
EP 1586309A1 · 2005 [cited by applicant]
EP 1100460B1 · 2008 [cited by applicant]
EP 1339389B1 · 2008 [cited by applicant]
EP 2359860A2 · 2011 [cited by applicant]
FR 2741628A1 · 1997 [cited by applicant]
GB 866381A · 1961 [cited by applicant]
JP 2242996A · 1990 [cited by applicant]
JP 7507548A · 1995 [cited by applicant]
JP 9505286A · 1997 [cited by applicant]
JP 9208494A · 1997 [cited by applicant]
JP 2000503663A · 2000 [cited by applicant]
JP 2000514457A · 2000 [cited by applicant]
JP 2003525243A · 2003 [cited by applicant]
JP 2005524730A · 2005 [cited by applicant]
JP 2005535638A · 2005 [cited by applicant]
JP 2007512094A · 2007 [cited by applicant]
JP 2007513226A · 2007 [cited by applicant]
JP 2007519756A · 2007 [cited by applicant]
JP 2008505716A · 2008 [cited by applicant]
JP 2008510004A · 2008 [cited by applicant]
JP 2008542293A · 2008 [cited by applicant]
JP 2009515669A · 2009 [cited by applicant]
JP 2010513954A · 2010 [cited by applicant]
JP 2010215562A · 2010 [cited by applicant]
JP 2011518187A · 2011 [cited by applicant]
JP 2012509318A · 2012 [cited by applicant]
MX 2013007682A · 2013 [cited by applicant]
WO WO8802625A1 · 1988 [cited by applicant]
WO WO9300070A1 · 1993 [cited by applicant]
WO WO9324154A1 · 1993 [cited by applicant]
WO WO9503357A1 · 1995 [cited by applicant]
WO WO9513814A1 · 1995 [cited by applicant]
WO WO9710849A1 · 1997 [cited by applicant]
WO WO9802171A1 · 1998 [cited by applicant]
WO WO9621427A1 · 1998 [cited by applicant]
WO WO9921908A1 · 1999 [cited by applicant]
WO WO0145742A1 · 2001 [cited by applicant]
WO WO0182970A1 · 2001 [cited by applicant]
WO WO0245689A1 · 2002 [cited by applicant]
WO WO02102376A1 · 2002 [cited by applicant]
WO WO03017990A2 · 2003 [cited by applicant]
WO WO03041685A1 · 2003 [cited by applicant]
WO WO03093344A1 · 2003 [cited by applicant]
WO WO2004039355A1 · 2004 [cited by applicant]
WO WO2005051449A1 · 2005 [cited by applicant]
WO WO2005054319A1 · 2005 [cited by applicant]
WO WO2005070332A1 · 2005 [cited by applicant]
WO WO2005074913A2 · 2005 [cited by applicant]
WO WO2006010066A2 · 2006 [cited by applicant]
WO WO2006127953A2 · 2006 [cited by applicant]
WO WO2007011955A2 · 2007 [cited by applicant]
WO WO2007019439A2 · 2007 [cited by applicant]
WO WO2007061896A1 · 2007 [cited by applicant]
WO WO2008076729A1 · 2008 [cited by applicant]
WO WO2008153611A2 · 2008 [cited by applicant]
WO WO2009060473A2 · 2009 [cited by applicant]
WO WO2009129509A2 · 2009 [cited by applicant]
WO WO2009132050A2 · 2009 [cited by applicant]
WO WO2011154724A2 · 2011 [cited by applicant]
WO WO2012090070A2 · 2012 [cited by applicant]
WO WO2012131106A1 · 2012 [cited by applicant]
WO WO2014001904A1 · 2014 [cited by applicant]
WO WO2018015915A1 · 2018 [cited by applicant]
WO WO2018227293A1 · 2018 [cited by applicant]
Cerrai et al., “Block copolymers of L-lactide and poly(ethylene glycol) for biomedical applications”. Journal of Materials Science: Materials in Medicine, vol. 5 (1994) pp. 308-313. [cited by applicant]
International Search Report issued in International Application No. PCT/IB2011/003323 on Aug. 9, 2012. [cited by applicant]
Li, “Bioresorbable Hydrogels Prepared Through Stereocomplexation between Poly (L-lactide) and Poly (D-lactide) Blocks Attrached to Poly(ethylene glycol)”, Macromolecular Bioscience, vol. 3, No. 11 (2003) pp. 657-661. [cited by applicant]
Baimark et al., “Biodegradable nanoparticles of methoxy poly(ethylene glycol)-b-poly(D,L-lactide)/methoxy poly(ethylene glycol)-b-poly(E-caprolactone) blends for drug delivery,” Nanoscale Research Letters, vol. 7, No. 2… [cited by applicant]
Bédouet et al., “Intra-articular Fate of Degradable Poly(ethyleneglycol)-hydrogel Microspheres as Carriers for Sustained Drug Delivery”, International Journal of Pharmaceutics, vol. 456, No. 2 (2013) pp. 536-544. [cited by applicant]
Chen et al., “In vitro release of levonorgestrel from phase sensitive and thermosensitive smart polymer delivery systems,” Pharmaceutilal development and technology, vol. 10, No. 2, 2005, pp. 319-325 (2 pages, Abstract … [cited by applicant]
Fang et al., “Acute Toxicity evaluation of in situ gel-forming controlled drug delivery system based on biodegradable poly(E-caprolactone)-poly(ethylene glycol)-poly(E-caprolactone) copolymer,” Biomed. Mater., vol. 4, N… [cited by applicant]
Fujiwara et al., “Novel Thermo-Responsive Formation of a Hydrogel by Stereo-Complexation between PLLA-PEG-PLLA and PDLA-PEG-PDLA Block Copolymers,” Macromol. Biosci., vol. 1, No. 5, 2001, pp. 204-208. [cited by applicant]
Higaki, “Recent development of nanomedicine for the treatment of inflammatory diseases,” Inflammation and Regeneration, vol. 29, No. 2, Mar. 2009, pp. 112-117. [cited by applicant]
International Preliminary Report on Patentability issued in corresponding PCT Application No. PCT/IB2016/001815 on May 31, 2018. [cited by applicant]
International Search Report for International Application No. PCT/IB2013/001547, dated Dec. 3, 2013. [cited by applicant]
International Search Report issued in corresponding PCT Application No. PCT/IB2016/001815 on Feb. 27, 2017. [cited by applicant]
Mao et al., “In Situ Formation and Gelation Mechanism of Thermoresponsive Stereocomplexed Hydrogels Upon Mixing Diblock and Triblock Poly(lactic Acid)/Poly(ethylene Glycol) Copolymers,” J Phys Chem B, vol. 119, No. 21, … [cited by applicant]
McKenzie et al., “Proof-of-Concept of Polymeric Sol-Gels in Multi-Drug Delivery and Intraoperative Image-Guided Surgery for Peritoneal Ovarian Cancer,” Pharm Res, Jun. 9, 2016, 9 pages. [cited by applicant]
Petit et al., “Sustained Intra-Articular Replease of Celecoxib from in situ Forming Gels Made of Acetyl-Capped PCLA-PEG-PCLA Triblock Copolymers in Horses”, Biomaterials, vol. 53 (2015) pp. 426-436. [cited by applicant]
Singaporean Search Report for Singaporean Application No. 11201408658P, dated Dec. 23, 2015. [cited by applicant]
Yu et al., “Biodegradability and Biocompatibility of Thermoreversible Hydrogels Formed from Mixing a Sol and a Precipitate of a Block Copolymers in Water,” Biomacromolecules, vol. 11, No. 8, 2010 (published online Jul. … [cited by applicant]
Yu et al., “Mixing a Sol and a Precipitate of a Block Copolymers with Different Block Ratios Leads to an Injectable Hydrogel,” Biomacromolecules, vol. 10, No. 6, 2009 (published online Apr. 22, 2009), pp. 1547-1553. [cited by applicant]
Crofford et al., “Basic biology and clinical application of specific cyclooxygenase-2 inhibitors,” Arthritis & Rheumatism, vol. 43, No. 1, Jan. 2000, pp. 4-13. [cited by applicant]
Devries et al., “On the edge: the physiological and pathophysiological role of chemokines during inflammatory and immunological responses,” Seminars in Immunology, vol. 11, 1999, pp. 95-104. [cited by applicant]
Morgen et al., “Nanoparticles for Improved Local Retention after Intra-Articular Injection into the Knee Joint,” Pharm Res, vol. 30, 2013, pp. 257-268. [cited by applicant]
Thakkar et al., “Enhanced Retention of Celecoxib-Loaded Solid Lipid Nanoparticles after Intra-Articular Administration,” Drugs R D, vol. 8, No. 5, 2007, pp. 275-285. [cited by applicant]